Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elcubragistat (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Abide Therapeutics; Lundbeck A/S

Most Recent Events

  • 10 Jul 2019 Status changed from active, no longer recruiting to completed.
  • 29 May 2019 Lundbeck A/S after having received customary regulatory approvals has acquired Abide Therapeutics Inc.
  • 13 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top